Cargando…

Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. A substantial proportion of patients with PCOS are either overweight or obese, and excess body weight aggravates the hormonal, reproductive and metabolic manifestations of PCOS. In recent years, several stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kourtidou, Christodoula, Tziomalos, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953739/
https://www.ncbi.nlm.nih.gov/pubmed/36831032
http://dx.doi.org/10.3390/biomedicines11020496
_version_ 1784893952839647232
author Kourtidou, Christodoula
Tziomalos, Konstantinos
author_facet Kourtidou, Christodoula
Tziomalos, Konstantinos
author_sort Kourtidou, Christodoula
collection PubMed
description Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. A substantial proportion of patients with PCOS are either overweight or obese, and excess body weight aggravates the hormonal, reproductive and metabolic manifestations of PCOS. In recent years, several studies evaluated the role of various pharmacological agents in the management of obesity in this population. Most reports assessed glucagon-like peptide-1 receptor agonists and showed a substantial reduction in body weight. More limited data suggest that sodium-glucose cotransporter-2 inhibitors and phosphodiesterase-4 inhibitors might also be effective in the management of obesity in these patients. In the present review, we discuss the current evidence on the safety and efficacy of these agents in overweight and obese patients with PCOS.
format Online
Article
Text
id pubmed-9953739
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99537392023-02-25 Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome Kourtidou, Christodoula Tziomalos, Konstantinos Biomedicines Communication Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. A substantial proportion of patients with PCOS are either overweight or obese, and excess body weight aggravates the hormonal, reproductive and metabolic manifestations of PCOS. In recent years, several studies evaluated the role of various pharmacological agents in the management of obesity in this population. Most reports assessed glucagon-like peptide-1 receptor agonists and showed a substantial reduction in body weight. More limited data suggest that sodium-glucose cotransporter-2 inhibitors and phosphodiesterase-4 inhibitors might also be effective in the management of obesity in these patients. In the present review, we discuss the current evidence on the safety and efficacy of these agents in overweight and obese patients with PCOS. MDPI 2023-02-08 /pmc/articles/PMC9953739/ /pubmed/36831032 http://dx.doi.org/10.3390/biomedicines11020496 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Kourtidou, Christodoula
Tziomalos, Konstantinos
Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
title Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
title_full Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
title_fullStr Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
title_full_unstemmed Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
title_short Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
title_sort pharmacological management of obesity in patients with polycystic ovary syndrome
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953739/
https://www.ncbi.nlm.nih.gov/pubmed/36831032
http://dx.doi.org/10.3390/biomedicines11020496
work_keys_str_mv AT kourtidouchristodoula pharmacologicalmanagementofobesityinpatientswithpolycysticovarysyndrome
AT tziomaloskonstantinos pharmacologicalmanagementofobesityinpatientswithpolycysticovarysyndrome